Cyagen White Paper: Infectivity and Immune Mechanisms of Coronaviruses & SARS-CoV-2

-
An outbreak of COVID-19 (Coronavirus Disease in 2019) caused by the novel coronavirus, officially named SARS-CoV-2, swept across the world from Wuhan at the end of 2019 - having since brought a huge impact on the lives of people both in China and abroad. The World Health Organization’s (WHO) Emergency Committee declared the SARS-CoV-2 outbreak to be a Public Health Emergency of International Concern (PHEIC) on January 30, 2020. In order to effectively address COVID-19 as a public health threat, we need an in-depth understanding of its infection and immune mechanisms. Our experts have investigated the known characteristics of SARS-CoV-2, similarities to related coronaviruses, potential antiviral targets, and lessons learned from the outbreak from a research perspective – which we have assembled to assist in such research efforts.

As we know, SARS-CoV uses angiotensin-converting enzyme (ACE2) as a receptor for mediating cell entry and mainly infects epithelial cells of both the tracheobronchial tree and type II pneumocytes. On the other hand, MERS-CoV uses dipeptidyl peptidase-4 (DPP4, also known as CD26) as a receptor to infect both undifferentiated bronchial epithelial cells and type II pneumocytes. It is now known that the receptor binding domain (RBD) of both SARS-CoV-2 and SARS-CoV share a high homology; both coronaviruses interact with the host through binding interactions of the virus Spike protein and human ACE2 receptor protein.

What you can learn from this White Paper:
  1. The brief introduction to Coronavirus
  2. The Characteristics and Correlations of SARS-CoV, MERS-CoV, and SARS-CoV-2
  3. Methods to defend against COVID-19
  4. What we have learned from the 2019 outbreak

In the paper, we discuss various research opportunities to combat the COVID-19 outbreak, including: targeted immunotherapy, SC-1 peptide, SARS-CoV-2 S-RBD neutralizing monoclonal antibodies (mAbs), and vaccine development based on human receptor ACE2. Accurate animal models are necessary for verifying the pathogenesis and immune mechanisms of the illness to accelerate research across vaccine development, new antiviral drug development, gene therapy, and more. Since the outbreak, the R&D team at Cyagen has made every effort to develop animal models tailored to the global SARS-CoV-2 research initiative. As our way of contributing to the international epidemic prevention effort, we are opening services on accurate models for coronavirus receptor targets, such as ACE2 and DPP4, effective immediately.
Cyagen is prioritizing production of ACE2 mice to support research on COVID-19, the disease caused by SARS-CoV-2 virus. Effective immediately, we are opening orders for ACE2 KO, Humanized, and Rosa26 KI mouse models.





Comments

Post a Comment

Popular posts from this blog

Knockout by CRISPR vs Knockdown by shRNA

-
In solving the mystery of gene function, there is no more important clue than the phenotype of inactivating the gene of interest. With a plethora of methods available, researchers must first determine what approach is best for their specific scientific questions and experimental systems. For over a decade, RNA-interference-based methods of gene knockdown (i.e. RNAi & shRNA) have provided a wealth of insight into gene function, but in recent years the advent of CRISPR- and TALEN-based methods now allow genome editing to be used to quickly and efficiently test the effect of gene knockouts. Here, we review the advantages and disadvantages of these approaches, and describe some experimental situations in which one approach is better than another, focusing primarily on CRISPR/Cas9 and shRNA. For a discussion of the relative advantages of CRISPR/Cas9 versus TALEN , see our prior Newsletter on this topic. CRISPR Knockout In this method, a guide RNA (gRNA) homologous to an 18-22nt ta...
Read more

Extending Lifespan of Mice, Then Human

-
Image
Invariably, everyone gets old. However, as a true testament to human stubbornness, research toward a “cure” for aging has never stopped. Over the past few decades, various approaches have allowed scientists to generate animal models with extended lifespans. In recent years, this trend has moved from lower organisms to mammalian model systems. There are now several rodent models with enhanced longevity. Many of these models are directly relevant to human aging. A new study has identified a deletion in exon 3 of human growth hormone receptor (GHR) to be prevalent in naturally long-lived men (1). The presence of two copies of this mutation may allow men to live about ten years longer than they otherwise would. This agrees with many findings from rodent models. Transgenic mice that overexpress GH age rapidly, while knockout mice lacking GHR are long-lived (2,3). In humans and mice, IGF1 signaling is also closely linked to longevity via a signaling pathway overlapping that of GH (4,5). ...
Read more

Healing a broken heart

-
Image
Introduction: Reduced heart function due to aging and disease is a major health problem. Heart attacks can have devastating impacts, often leading to the death of the patient or chronic morbidity for those that survive. A major reason for the sensitivity of the circulatory system to heart malfunction is that heart muscle cells (cardiomyocytes) of adult mammals generally do not divide. This means that when a cardiomyocyte dies, due to localized loss of blood supply, for example, that dead cell will never be replaced. Normally, heart tissue has a robust, healthy blood supply, but when a heart attack strikes, portions of heart tissue are deprived of blood flow, resulting in rapid cell death in those sections of the heart. Recovering the ability to heal Interestingly, newborn hearts can heal. In 2011, scientists discovered that newborn mice are able to regenerate cardiomyocytes to repair heart damage, but this ability is lost soon after birth (1). More recently, researchers disc...
Read more